Background: Integrity of hemoglobin is a crucial determining factor for the overall health functions. Nutrient repletion therapy should be a fundamental strategy to restore the healthy properties of blood. A unique patent-pending iron-free VMP35 formulation was engineered by our laboratory to restore iron-dependent hemoglobin in anemic cells using a proprietary Prodosome® absorption technology. This formulation, containing an array of nano-emulsified botanical ingredients rich in bioflavonoids, strengthens the structural integrity of connective tissues, and potentiates immune competence, cellular aerobic metabolism, and enhances efficient regulation of inflammatory events. We discuss the intricate aspects of strong vs. fragile immunity and consequential inflammatory responses to convey a deeper understanding of the varied and overly complex sequela of immunological behaviors and events. The effect of the VMP35 is mediated through highly absorbable nutritional/nutrigenomic repletion enabling improvements in the systemic set of functional behaviors. In fact, the iron-free VMP35 facilitates a “Systems Biology Approach” which restores hemoglobin status, reverses anaerobic hypoxia, improves competent immune responsivity, and regulates appropriate and controlled activation of inflammatory sequela. Under these pathogenic circumstances, iron-deficiency anemia has been misconceptualized, and a new nosological term, Chronic Anemia Syndrome, is proposed. The comparative therapeutic rationale of Reductionist vs. Systems Biology approaches is also explained in detail. Methods: The efficacy of the novel therapeutic iron-free VMP35 liquid nutraceutical is detailed in restoring iron-dependent hemoglobin to RBCs and boosting cellular morphology, viability, and immune competence, thereby reducing the need for prolonging inflammatory sequela. Results: This was demonstrated in a previous IRB approved multi-subject human study. In addition, two recent case studies report dramatic restorative benefits of nutrient repletion therapy of the VMP35 on subjects having experienced near-fatal events, which confirmed the findings explained in this manuscript. Conclusions: This novel iron-free VMP35 modulates an array of homeostatic biological parameters such as enhanced hemoglobinization, aerobic metabolism, viral immuno-competence, and inflammatory regulation. Further research, examining mechanistic and beneficial effects in athletic performance, is in progress. Importantly, during these troubled immune challenging times, modulating an array of homeostatic immunological and inflammatory dysfunctions are tantamount to improved population outcomes. Trial Registration: The Clinical investigation in a total of 38 subjects was conducted under an Institutional Review Board (IRB) from the Path Foundation in New York, NY (#13-009 April 25, 2013). The two case studies were done at Lancaster General Hospital, Lancaster, PA, and Jefferson University Hospital, Philadelphia, PA, USA. Both studies were retrospectively registered.

According to the NHLBI, more than 3 million Americans suffer from Anemia, the most prevalent blood disorder, while anemia affects 1.93 billion people worldwide (24.8% of the world population). Several degenerative diseases are associated with anemia. Substantial loss of blood causes massive alterations in blood parameters including reduced iron leading to anemia. However, it is the authors’ assertion that chronic iron deficiency anemia has been misconceptualized. We hereby propose a new concept termed Chronic Anemia Syndrome (CAS). CAS is the result of a diminishing reservoir of primary alkaline buffers promoting an increased anaerobic/acidic/hypoxic biological environment and pathological events, which are characteristic of almost all chronic degenerative diseases. Diminishing primary alkaline buffers induce chronic inflammatory and pathophysiological conditions promoting a defensive expenditure of secondary alkalinizing buffers from hemoglobin (i.e. histidine), to prevent a dangerous lowering of blood pH. In the process of liberating histidine from heme protein, iron is cleaved from heme groups; rapidly transported out of the blood circulation; and deposited into other vital organs including hepatic tissues, GI tract tissues; bone marrow, etc., Upon examining results of a blood test, the common diagnosis is iron‐deficient anemia. Moreover, excessive accumulation of iron in the tissues can lead to hemochromatosis, also termed “iron‐overload anemia”, a potentially life‐threatening condition. As such, it is the researchers notion that iron deficiency anemia is not actually caused by an iron deficiency; but by a deficiency in alkaline buffers. To test this hypothesis a randomized controlled one‐way cross‐over clinical investigation was conducted in 38 subjects (men = 10; women = 28; age: 22–82 years). This study evaluated the efficacy of VMP35 multi‐nutrient complex (MNC), a non‐iron containing liquid nutraceutical supplement, on the rate of absorption; restoration of hemoglobin; and its effects on various other properties of the blood. Subjects consumed either placebo or VMP35 (30 ml) and held the sample in their mouth for 30 seconds and swallowed, after which blood was taken at 5 min and/or 30 min. We evaluated properties of live blood within 30 seconds of lancing the fingers following meticulous and methodical procedures to critically assess, via a live blood cell imaging (LBCI) technology using phase contrast microscopy, the changes in peripheral blood smears in all 38 subjects. The iron‐free VMP35 caused positive changes in blood including morphological, hematological (including restoration of hemoglobin) and rheological changes 5 min after intake, which were sustained for at least 30 min. Taken together, the VMP35 non‐iron nutraceutical supplement caused remarkable improvements in blood integrity, including blood morphology and rheology, and rapidly and substantially restored hemoglobin in RBCs. No changes in placebos were observed and no adverse events were reported. Support or Funding Information The Study ...

Impaired digestive competence and consequential sluggish immune and metabolic sequela are epidemic‐sized health problems in modern cultures. Since digestion is the first step of metabolism, implementing novel strategies to restore digestive and metabolic competence are important health priorities. N‐SORB is a patent‐pending KD120 multienzyme complex composed of metabolically activated natural digestive‐type enzymes encapsulated in a high‐potency phosphatidylcholine non‐GMO soy lecithin SK713 SLP absorption technology (Prodosome®). A randomized, double‐blind placebo‐controlled study was conducted in 46 male and female healthy volunteers (age: 25.8 ± 12.1 years) to assess the safety and efficacy of N‐SORB. Subjects received either N‐SORB (1 mL, twice daily) or the same amount of placebo for 90 consecutive days. Body weight, blood pressure, physical health, and complete blood chemistries including blood glucose, liver enzymes, and lipid profiles; and immune health, physical health, sleep quality and quality of life parameters were assessed pre‐ and post‐intervention. Serum cytokine levels were determined by using a Bio‐Plex Pro Human Cytokine 8‐plex assay and ELISA. Whole body composition analysis was performed by dual‐energy X‐Ray absorptiometry (DEXA) to determine body fat mass, lean mass and android and gynoid fat. Quality of life (QOL) and sleep quality were assessed using WHOQOL‐BREF and Pittsburgh Sleep Quality Index (PSQI) questionnaire. Adverse events were strictly monitored. 40 subjects completed the study. Hematocrit, hemoglobin, mean corpuscular volume, platelets and lymphocytes provide evidence indicating consistent trends of improvement in the N‐SORB group. QOL parameters showed a small but significant improvement in the N‐SORB group. A significant increase was observed in AST levels in the placebo group at the end of 90 days of treatment, indicating increased liver distress. However, no increase was observed in the N‐SORB group. No significant changes in BUN, serum creatinine, ALP, ALT, and lipid profile were observed between the placebo and treatment groups before and after the 90‐day intervention. No adverse effects were reported. This 90‐day intervention study with N‐SORB clearly exhibited trends of improvement in RBC and immune parameters and found improvements in QOL and sleep quality scivnin already healthy volunteers. The N‐SORB treatment group experienced significant improvement in gastrointestinal functions, immune and metabolic parameters and other systemic improvements. No adverse events were reported. Support or Funding Information The Project was partially sponsored by VNI Inc, Lederach, PA

Objectives Optimal nutrition and natural digestive enzymes play a critical role in enhancing healthy digestion. N-SORB, a novel KD120 liquid multienzyme complex was developed and encapsulated using a SK713 SLP absorption technology (Prodosome®). A randomized, double-blind placebo-controlled investigation over a period of 90 consecutive days was conducted to determine the safety and efficacy of N-SORB on diverse parameters of the blood, immune health and physical health. Methods Forty-six (age: 25.8 ± 12.1 years) healthy volunteers received either N-SORB or placebo for 90 consecutive days. Complete blood count, as well as blood glucose, liver enzymes, and lipid profile were assessed pre- and post-intervention. Serum cytokine levels were determined using ELISA. Whole Body composition analysis was performed by DEXA to determine body fat mass, lean mass and android and gynoid fat. Body weight, blood pressure, and physical health were assessed. Changes in quality of life (QOL) were examined using WHOQOL-BREF questionnaire. Sleep quality was assessed using Pittsburgh Sleep Quality Index (PSQI) questionnaire. Adverse events were monitored. This clinical investigation was followed by three case studies. Results 40 subjects completed the study. Compared to placebo, changes in blood cell counts including hematocrit, hemoglobin, mean corpuscular volume, platelets and lymphocytes provide evidence indicating consistent trends of improvement. QOL parameters showed significant improvement in N-SORB group. A significant increase was observed in AST level in the placebo group, while, no increase was observed in the N-SORB group. In either group, no significant changes in BUN, serum creatinine, ALP, ALT, and lipid profile were observed. No adverse effects were reported. Case study volunteers also reported encouraging results. Conclusions N-SORB exhibited trends of improvement in some RBC and immune parameters and found improvements in QOL and PSQI; but didn't significantly alter cardiometabolic parameters, lipid profile or body composition. N-SORB induced significant improvement in digestive health, metabolism and sleep pattern. Case studies indicated significant improvement in digestion, sleep pattern and metabolic health. Funding Sources This Project was funded by VNI Inc, Lederach, PA.

Digestive enzymes have been historically consumed to enhance disintegration and dissolution of foodstuffs in the stomach. N‐Sorb is a novel KD120 multi‐enzyme complex (MEC) containing a range of protease, amylase, and lipase enzymes and including glucoamylase and alpha‐galactosidase. Unlike conventional digestive enzymes, these enzymes are activated in pH environments ranging from 6.5 to 8.5. These enzymes are encapsulated in a patent‐pending SK713 Soy Lecithin Phospholipid absorption technology (‘Prodosomes’) to facilitate rapid absorption and delivery into the blood, and increase availability to tissues. Eleven case studies from two independent clinics (one in California and one in Pennsylvania) are reported in this presentation under the strict supervision of two physicians. Eleven male and female volunteers (age: 20 to 71 years) suffering from gut related digestive problems including digestive dysfunctions and leaky gut, as well as gluten allergy, consumed a minimum of one dose (1/8 tsp Prodosomes and 1/8 tsp enzyme powder mixed into 4 ounces of water) two times per day on an empty stomach over different periods of time ranging from 1 month to 4 months. Subjects were compliant based on product usage and replacement. All subjects reported significant improvement in gastrointestinal functions among other systemic improvements. No adverse events were observed in these volunteers.Support or Funding InformationVNI Inc, Lederach, PA, funded this research project